The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation.
Pulmonary vascular remodeling and inflammation often coexist in clinical and experimentally induced pulmonary arterial hypertension (PAH). In some instances, the pulmonary hypertension may be the primary, or at least the initial, problem, while inflammatory or autoimmune responses appear to initiate or dominate the picture in other cases. Based on studies in a model of PAH resulting from targeted deletion of the neuropeptide vasoactive intestinal peptide (VIP) gene, we propose that, at least in this experimental model, but possibly also in other situations, both vascular remodeling and inflammation may be mediated by one and the same mechanism: uncontrolled activation of calcineurin-NFAT (nuclear factor of activated T cells) signaling. If this hypothesis is validated, VIP would emerge as an endogenous modulator of pulmonary vascular remodeling and inflammation, through its suppression of NFAT activation.
Said
Sami I
SI
Pulmonary and Critical Care Medicine, SUNY Health Sciences Center, Stony Brook, NY 11794-8172, USA. sami.i.said@stonybrook.edu
D000818:Animals; D006976:Hypertension, Pulmonary / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008168:Lung / Q000098:blood supply* / Q000378:metabolism*; D051379:Mice; D023421:Models, Animal; D008954:Models, Biological; D050778:NFATC Transcription Factors / Q000378:metabolism; D011014:Pneumonia / Q000378:metabolism*; D011651:Pulmonary Artery / Q000378:metabolism / Q000473:pathology; D051381:Rats; D014660:Vasoactive Intestinal Peptide / Q000235:genetics / Q000502:physiology*
D050778:NFATC Transcription Factors; D014660:Vasoactive Intestinal Peptide